Mallinckrodt’s Xartemis XR Clears FDA, But Without Abuse-Deterrent Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Xartemis XR, the first extended-release oral combination of oxycodone and acetaminophen, will offer twice-daily dosing, but Purdue Pharma’s OxyContin will remain the only opioid drug on the market with abuse-deterrent claims in labeling.